Estrogen Receptor α and Progesterone Receptor Expression in Ovarian Adult Granulosa Cell Tumors and Sertoli-Leydig Cell Tumors

Farinola, Maryam A.; Gown, Allen M.; Judson, Kara; Ronnett, Brigitte M.; Barry, Todd; Movahedi–Lankarani, Saeid; Vang, Russell

doi:10.1097/pgp.0b013e31805c0d99

Cited by 51 publications

(30 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whilst a potential role for some NR such as the steroidogenic factor-1 (SF-1) has been well characterized in the biology of GC, the patterns of expression of the other NR have not been systematically examined. Similarly, there is limited information on the role of NR in GCT; we have characterized the estrogen receptor (ER)-β in GCT [15] and others have examined ER-α, the progesterone receptor (PR), and SF-1 [16][17][18]. The role of other NR known to be expressed in GC has not been examined nor has there been a systematic expression profiling of the entire NR superfamily.…”

Section: Introductionmentioning

confidence: 96%

Nuclear Receptor Profiling of Ovarian Granulosa Cell Tumors

Alexiadis¹,

Eriksson

Jamieson

et al. 2011

HORM CANC

View full text Add to dashboard Cite

Granulosa cell tumors of the ovary (GCT) represent ~5% of malignant ovarian tumors. The adult form is defined by a mutation in the FOXL2 gene. GCT exhibit many of the features of normal proliferating granulosa cells. We have profiled the expression of the 48 human nuclear receptors (NR) by quantitative RT-PCR in a panel of GCT and in two GCT-derived cell lines, COV434 and KGN. The highest level of expression is seen for COUP-TF2 with abundant expression of PPARγ, SF-1, and TR-α. Estrogen receptor (ER)-β is the most abundant of the steroid receptors with relatively high expression also of AR, ER-α, and PR. The concordance of expression for each NR across the tumors is remarkably high with same discordance between the cell lines and the tumors, particularly the COV434 line. No significant differences were observed with respect to tumor stage for NR expression. These findings provide a full profile of NR expression in GCT which will enable full characterization of their roles and potential as therapeutic targets.

show abstract

Section: Introductionmentioning

confidence: 96%

Nuclear Receptor Profiling of Ovarian Granulosa Cell Tumors

Alexiadis¹,

Eriksson

Jamieson

et al. 2011

HORM CANC

View full text Add to dashboard Cite

show abstract

“…Estrogen can also act on the neighboring stromal tissue and via angiogenesis to promote tumor growth. Suppression of endogenous estrogen will provide an antiproliferative milieu which could be effective in treating GCT [12]. 5.…”

Section: Etiology and Risk Factorsmentioning

confidence: 99%

Recent Advances in Granulosa Cell Tumor Ovary: A Review

Kottarathil

Antony

Nair

et al. 2012

Indian J Surg Oncol

105

108

View full text Add to dashboard Cite

Granulosa cell tumors constitute less than 5 % of all ovarian tumors. Unlike epithelial ovarian tumors, they occur in a younger age group, are usually detected in an early stage and often have features of hyperestrogenism. The presenting symptoms are usually nonspecific with abdominal pain or distension. They follow an indolent course and are characterized by a long natural history. Mutation of FOXL2 (402C->G) seen in 97 % of adult GCT may be pathognomonic for adult GCT. Only stage of the disease has been consistently shown in various studies to affect survival of patients with GCT. The initial management of patients, for whom fertility is not an issue, is total abdominal hysterectomy, bilateral salpingo-oophorectomy and removal of all gross disease. Nodal dissection is not a significant factor for survival and is not recommended in surgical staging of GCT. Fertility preserving surgery with unilateral salpingooophorectomy is feasible in young patients with stage Ia GCT. Patients with early stage disease (stage I and II) have a very good prognosis with 5 year DFS and OS of 89 % and 99 % respectively and these groups of patients usually don't require any postoperative treatment. Patients with stage Ic disease associated with poor prognostic factors like large tumor size or high mitotic index and stage II, have a higher chance of relapse, and may benefit with postoperative treatment but role of chemotherapy is still debatable. In advanced stage disease (stage III and IV) the 5 year DFS and OS disease was 72 % and 80 % respectively hence the option of postoperative treatment with 6 cycles of BEP should be considered in this group. Recently paclitaxel is being investigated as an effective tool in GCT. The efficacy of radiation in GCT is not well defined but in optimally debulked cases postoperative radiation is a viable option. Due to high chance of recurrence even years after apparent clinical cure of the primary tumor, lifelong follow up with clinical examination and tumor markers like inhibin B is recommended. About 25 % GCT develop recurrence and the median time to recur is usually 4-5 years. Most recurrences are intraperitoneal and usually a complete debulking of the disease is feasible even in the recurrent setting. Postoperative chemotherapy (platinum based) is usually given after surgery more so in cases with widespread disease or after suboptimal cytoreduction. Recurrent chemoresistant, progressive non-responding GCT or patients with high surgical risk are ideal candidates for targeted therapy.

show abstract

“…117,215,219 The Differential Diagnosis of Fallopian Tube Lesions Primary epithelial tumors of the fallopian tube and paratubal region demonstrate similar morphologic and immunohistochemical features as those of the ovary and peritoneum. Differentiating markers characteristic of the anatomic location of these tumors do not exist.…”

mentioning

confidence: 99%

The Utility of Immunohistochemistry in the Differential Diagnosis of Gynecologic Disorders

Kaspar

Crum

2015

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context Immunohistochemistry has assumed an increasing role in the identification and characterization of gynecologic disorders including lesions with deceptively bland morphology, uncommon and underdiagnosed neoplasms, and neoplasms with specific genetic alterations associated with overexpression or loss of expression of specific proteins. The diagnostic accuracy has been significantly improved owing to the discovery and increasing experience with the tumor-associated biomarkers, and the increasing demand for precise tumor classification to assess suitability for the expanding therapeutic modalities including clinical trials. Objective To differentiate lesions of the gynecologic tract through the use of effective immunohistochemical panels. Data Sources Literature review and authors' personal practice experience. Conclusions The application of diagnostic and prognostic immunohistochemical panels has enabled pathologists to better guide therapeutic decisions and to better predict the clinical outcome. It is now well established that the use of ancillary testing, including immunohistochemistry, has a significant power in the identification, differentiation, and classification of reactive, premalignant, and malignant gynecologic disorders. This article discusses the utilities and pitfalls of the commonly used immunohistochemical markers in the context of overlapping morphologic features encountered in the uterus, ovaries, and fallopian tubes.

show abstract

Estrogen Receptor α and Progesterone Receptor Expression in Ovarian Adult Granulosa Cell Tumors and Sertoli-Leydig Cell Tumors

Cited by 51 publications

References 26 publications

Nuclear Receptor Profiling of Ovarian Granulosa Cell Tumors

Nuclear Receptor Profiling of Ovarian Granulosa Cell Tumors

Recent Advances in Granulosa Cell Tumor Ovary: A Review

The Utility of Immunohistochemistry in the Differential Diagnosis of Gynecologic Disorders

Contact Info

Product

Resources

About